Latest Safety News

Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.

Ansell Limited has revealed unauthorized access to certain company data through vulnerabilities in licensed third-party software, with no disruption to operations. While most accessed data was non-sensitive, some confidential and personal information was involved.

Paladin Energy reports a record uranium production quarter at its Langer Heinrich Mine alongside a robust engineering review of its Patterson Lake South Project, supported by a successful A$300 million equity raise.

Paladin Energy reported a record uranium production quarter at its Langer Heinrich Mine alongside a successful A$300 million equity raise, positioning the company for accelerated development of its Patterson Lake South project.

Rio Tinto reported robust third quarter 2025 production results, highlighted by record outputs in bauxite and copper, and an upgraded bauxite production forecast. Key projects like Simandou and Oyu Tolgoi continue to progress on schedule, underpinning the company’s growth trajectory.

TMK Energy reports a significant 60% increase in gas production at its Gurvantes XXXV Pilot Well Project in September 2025, driven by improved drilling techniques and strategic reservoir management despite operational challenges.

ClearVue Technologies has raised A$4.6 million in a strongly supported placement to accelerate international certification and ongoing innovation of its solar façade products.

Harvest Technology Group has resolved a longstanding dispute over the Vos Shine vessel, receiving A$725,000 in settlement proceeds that will positively impact its financials.

PYC Therapeutics has reported encouraging pre-clinical results for its RNA therapy candidate PYC-002 targeting Phelan-McDermid Syndrome, supporting plans to enter human trials in 2026. The data demonstrate safety, brain distribution, and gene expression restoration in key disease regions.

Core Lithium has significantly increased its Ore Reserves at the Finniss Lithium Project by 42%, secured $54.3 million in fresh capital, and cleared all offtake obligations to advance its restart plans.

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.

DPM Metals reports solid third quarter production growth at its Bulgarian mines and steady progress integrating the newly acquired Vareš operation, setting the stage for future expansion.